Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 H167_N173del |
Therapy | Zoligratinib |
Indication/Tumor Type | intrahepatic cholangiocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 H167_N173del | intrahepatic cholangiocarcinoma | predicted - sensitive | Zoligratinib | Case Reports/Case Series | Actionable | In a clinical study, Debio 1347 treatment resulted in durable partial response of 11 months in 2 patients with intrahepatic cholangiocarcinoma harboring FGFR2 H167_N173del (J Clin Oncol 38, 2020 (suppl 4; abstr 567)). | detail... |
FGFR2 H167_N173del | intrahepatic cholangiocarcinoma | predicted - sensitive | Zoligratinib | Case Reports/Case Series | Actionable | In a Phase I trial, Debio 1347 treatment led to 51% tumor reduction and a progression-free survival of 13 months in an intrahepatic cholangiocarcinoma patient harboring FGFR2 H167_N173del, which was consistent with inhibition of growth in an intrahepatic cholangiocarcinoma cell line expressing FGFR2 H167_N173del in culture (PMID: 33926920; NCT01948297). | 33926920 |
PubMed Id | Reference Title | Details |
---|---|---|
Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma. | Full reference... | |
(33926920) | FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. | Full reference... |